An internal Centers for Disease Control and Prevention document said the Delta variant was as contagious as chicken pox. Vaccinated people who experience breakthrough infections can spread the virus, Dr. Rochelle Walensky noted. (The New York Times)
In the wake of controversy around Biogen’s Adulhelm, AbbVie announced plans to develop a molecule to treat Alzheimer’s disease. The company also dropped its Phase II tau program, ABBV-8E12. (Endpoints News)
Asian countries have imposed stricter COVID-19 restrictions as Delta-fueled outbreaks flare. Japan announced states of emergency through the end of August in areas near Tokyo and Osaka. (Reuters)
Cassava Sciences reported that its Alzheimer’s drug, simufilam, improved cognition in patients in a small clinical trial. But scientists not involved in the trial argued the evidence isn’t well supported. (STAT)
Mobile clinics in Denver are attempting to reach neighborhoods with low vaccination rates using detailed maps and partnerships with community organizations. It’s part of the Biden administration’s vaccine push to go “neighborhood by neighborhood.” (Kaiser Health News)
